A case of Larotrectinib for salivary gland secretory carcinoma

DOI
  • Sato Ryo
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center
  • Kawasaki Tomonori
    Pathology, Saitama Medical University International Medical Center
  • Matsumura Satoko
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center
  • Inoue Hitoshi
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center
  • Ebihara Yasuhiro
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center
  • Nakahira Mitsuhiko
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center
  • Yamazaki Tomoko
    Head and Neck Surgery-Otorhinolaryngology, Saitama Medical University International Medical Center

Bibliographic Information

Other Title
  • 唾液腺分泌がんにラロトレクチニブを使用した1例

Search this article

Abstract

Salivary gland secretory carcinoma is a salivary gland malignancy listed in the new WHO classification revised in 2017. In this study, we experienced a case of parotid gland secretory carcinoma with cancerous pleural effusion due to pleural metastasis. Although radical surgery was not indicated, the ETV6-NTRK3 fusion gene was detected in the biopsy specimen, and so Larotrectinib, a tropomyosin receptor kinase inhibitor, was started. In response, tumor shrinkage, a decrease in cancerous pleural effusion, and improvement in subjective symptoms were observed. The medication was continued, and the patient’s disease has not worsened. Larotrectinib was approved for production and marketing in Japan in March 2021, and there is only one report of its use in Japan at the time of writing. This case is considered to be a valuable report of a rapid response to Larotrectinib after initiation of the drug.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top